Participants received either oral fenebrutinib twice daily or oral teriflunomide once daily for at least 96 weeks.
LiCellGrow was developed to assist therapy developers in determining the optimal culture conditions during process development.
The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally.
IDE study results at 24 months showed an 87.1% composite clinical success rate with the Synergy Disc.
